Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo

Translational Oncology

Volumn 4, Issue 2, 2011, Pages 92-100

  Bruyère, Céline ^a   Abeloos, Laurence ^b   Lamoral Theys, Delphine ^a   Senetta, Rebecca ^c   Mathieu, Véronique ^a   Le Mercier, Marie ^a   Kast, Richard E ^d   Cassoni, Paola ^c   Vandenbussche, Guy ^a   Kiss, Robert ^a   Lefranc, Florence ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BETA1 INTEGRIN; CAVEOLIN 1; CYSTEINE RICH PROTEIN 61; ERLOTINIB; SARACATINIB; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL INVASION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSKELETON; DRUG ANTAGONISM; DRUG EFFECT; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OLIGODENDROGLIOMA; POLYMERIZATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION;

EID: 79953653387     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10205     Document Type: Article

References (69)

1. Lefranc F, Sadeghi N, Camby I, Metens T, Dewitte O, and Kiss R (2006). Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther 6, 719-732.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
3. Lefranc F, Brotchi J, and Kiss R (2005). Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23, 2411-2422.
4. Le Calvé B, Rynkowski M, Le Mercier M, Bruyère C, Lonez C, Gras T, Haibe-Kains B, Bontempi G, Decaestecker C, Ruysschaert JM, et al. (2010). Long term in vitro treatment of human glioblastoma cells with temozolomide confers resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia 12, 727-739.
5. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, and Gilbert MR (2008). Correlation ofO6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMTactivity. J Clin Oncol 26, 4189-4199.
6. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, and Kondo S (2004). Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11, 448-457.
7. Katayama M, Kawaguchi T, Berger MS, and Pieper RO (2007). DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14, 548-558.
8. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, and Kaina B (2007). Apoptosis in malignant glioma cells triggered by the temozolomideinduced DNA lesion O6-methylguanine. Oncogene 26, 186-197.
9. Mathieu V, De Neve N, LeMercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, and Lefranc F (2008). Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10, 1383-1392.
10. Fisher T, Galanti G, Lavie G, Jacob-Hirsch J, Kventsel I, Zeligson S, Winkler R, Simon AJ, Amariglio N, Rechavi G, et al. (2007). Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme. Cancer J 13, 335-344.
11. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O'Byrne KJ, et al. (2005). Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23, 8932-8941.
12. Le Mercier M, Mathieu V, Haibe-Kains B, Bontempi G, Mijatovic T, Decaestecker C, Kiss R, and Lefranc F (2008). Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 67, 456-469.
13. Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, and Mathieu V (2008). Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 229, 172-183.
14. Mathieu V, Le Mercier M, De Neve N, Sauvage S, Gras T, Roland I, Lefranc F, and Kiss R (2007). Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 127, 2399-2410.
15. Amberger-Murphy V (2009). Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 9, 381-390.
16. Oliver L, Olivier C, Marhuenda FB, Campone M, and Vallette FM (2009). Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol 2, 263-284.
17. Mann GE, Yudilevich DL, and Sobrevia L (2003). Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 83, 183-252.
18. Stan RV (2005). Structure of caveolae. Biochim Biophys Acta 1746, 334-348.
19. Carver LA and Schnitzer JE (2003). Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 3, 571-581.
20. van Deurs B, Roepstorff K, Hommelgaard AM, and Sandvig K (2003). Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol 13, 92-100.
21. Burgermeister E, Liscovitch M, Rocken C, Schmid RM, and Ebert MP (2008). Caveats of caveolin-1 in cancer progression. Cancer Lett 268, 187-201.
22. Goetz JG, Lajoie P, Wiseman SM, and Nabi IR (2008). Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 27, 715-735.
23. Quest AF, Gutierrez-Pajares JL, and Torres VA (2008). Caveolin-1: an ambiguous partner in cell signalling and cancer. J Cell Mol Med 12, 1130-1150.
24. Cameron P, Liu C, Smart D, Hantus ST, Fick JR, and Cameron RS (2002). Caveolin-1 expression is maintained in rat and human astroglioma cell lines. Glia 37, 275-290.
25. Cassoni P, Senetta R, Castellano I, Ortolan E, Bosco M, Magnani I, and Ducati A (2007). Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am J Surg Pathol 31, 760-769.
26. Senetta R, Trevisan E, Ruda R, Maldi E, Molinaro L, Lefranc F, Chiusa L, Lanotte M, Soffietti R, and Cassoni P (2009). Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. J Neuropathol Exp Neurol 68, 425-431.
27. Silva WI, Maldonado HM, Velazquez G, Rubio-Dávila M, Miranda JD, Aquino E, Mayol N, Cruz-Torres A, Jardón J, and Salgado-Villanueva IK (2005). Caveolin isoform expression during differentiation of C6 glioma cells. Int J Dev Neurosci 23, 599-612.
28. Virgintino D, Robertson D, Errede M, Benagiano V, Tauer U, Roncali L, and Bertossi M (2002). Expression of caveolin-1 in human brain microvessels. Neuroscience 115, 145-152.
29. Belot N, Rorive S, Doyen I, Lefranc F, Bruyneel E, Dedecker R, Micik S, Brotchi J, Decaestecker C, Salmon I, et al. (2001). Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features. Glia 36, 375-390.
30. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R, and Salmon I (2002). Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95, 641-655.
31. Ingrassia L, Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, Sauvage S, El Yazidi M, Dehoux M, Berger W, et al. (2009). Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. J Med Chem 52, 1100-1114.
32. Lefranc F, Mijatovic T, Kondo Y, Sauvage S, Roland I, Debeir O, Krstic D, Vasic V, Gailly P, Kondo S, et al. (2008). Targeting the α1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery 62, 211-221.
33. Le Mercier M, Fortin S, Mathieu V, Roland etI, Spiegl-Kreinecker S, Haibe-Kains B, Bontempi G, Decaestecker C, Berger W, Lefranc F, et al. (2009). Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia 11, 485-496.
34. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MC, Zweifel C, Tolnay M, Wasner M, Mergenthaler S, et al. (2009). Tenascin-C is a novel RBPJκ-induced target gene for Notch signaling in gliomas. Cancer Res 69, 458-465.
35. Decaestecker C, Camby I, Gordower L, Dewitte O, Cras P, Martin JJ, Pasteels JL, Van Ham P, Brotchi J, Kiss R, et al. (1998). Characterization of astroglial versus oligodendroglial phenotypes in glioblastomas by means of quantitative morphonuclear variables generated by computer-assisted microscopy. J Neuropathol Exp Neurol 57, 791-802.
36. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P, Capelle L, Delattre JY, Poirier J, et al. (2001). Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60, 863-871.
37. Lefranc F, James S, Camby I, Gaussin JF, Darro F, Brotchi J, Gabius J, and Kiss R (2005). Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. J Neurosurg 102, 706-714.
38. Lefranc F, Sauvage S, Van Goietsenoven G, Mégalizzi V, Lamoral-Theys D, Debeir O, Spiegl-Kreinecker S, Berger W, Mathieu V, Decaestecker C, et al. (2009). Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Mol Cancer Ther 8, 1739-1750.
39. Megalizzi V, Mathieu V, Mijatovic T, Gailly P, Debeir O, De Neve N, Van Damme M, Bontempi G, Haibe-Kains B, Decaestecker C, et al. (2007). 4-IBP, a σ1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 9, 358-369.
40. Naslavsky N, Stein R, Yanai A, Friedlander G, and Taraboulos A (1997). Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J Biol Chem 272, 6324-6331.
41. Camby I, Decaestecker C, Lefranc F, Kaltner H, Gabius HJ, and Kiss R (2005). Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun 335, 27-35.
42. Martin S, Cosset EC, Terrand J, Maglott A, Takeda K, and Dontenwill M (2009). Caveolin-1 regulates glioblastoma aggressiveness through the control of α(5)β(1) integrin expression and modulates glioblastoma responsiveness to SJ749, an α(5)β(1) integrin antagonist. Biochim Biophys Acta 1793, 354-367.
43. Jin Y, Kim HP, Cao J, Zhang M, Ifedigbo E, and Choi AM (2009). Caveolin-1 regulates the secretion and cytoprotection of Cyr61 in hyperoxic cell death. FASEB J 23, 341-350.
44. Xie D, Yin D, Tong X, O'Kelly J, Mori A, Miller C, Black K, Gui D, Said JW, and Koeffler HP (2004). Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and β-catenin-TCF/Lef signaling pathways. Cancer Res 64, 1987-1996.
45. Ikota H, Kinjo S, Yokoo H, and Nakazato Y (2006). Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol 111, 475-482.
46. Gladson CL (1999). The extracellular matrix of gliomas: modulation of cell function. J Neuropathol Exp Neurol 58, 1029-1040.
47. Rutka JT (1986). The K.G. McKenzie award lecture-1986. Effects of extracellular matrix proteins on the growth and differentiation of an anaplastic glioma cell line. Can J Neurol Sci 13, 301-306.
48. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, Wilson MT, Campos-Gonzalez R, Bouzahzah B, Pestell RG, et al. (2000). Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol 14, 1750-1775.
49. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, Wheeler TM, Ayala G, Thompson TC, and KadmonD (2006). Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 12, 4872-4875.
50. Tahir SA, Ren C, Timme TL, Gdor Y, Hoogeveen R, Morrisett JD, Frolov A, Ayala G, Wheeler TM, and Thompson TC (2003). Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res 9, 3653-3659.
51. Djedid R, Kiss R, and Lefranc F (2009). Targeted therapy of glioblastomas: a 5-year view. Future Medicine 6, 351-370.
52. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, et al. (2009). Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15, 330-337.
53. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, et al. (2008). Stem cell-related "selfrenewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26, 3015-3024.
54. Preusser M, Charles Janzer R, Felsberg J, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T,Marosi C, et al. (2008). Anti-O6-methylguaninemethyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18, 520-532.
55. Le Mercier M, Fortin S, Mathieu V, Kiss R, and Lefranc F (2010). Galectins and gliomas. Brain Pathol 20, 17-27.
56. Cantiani L, Manara MC, Zucchini C, De Sanctis P, Zuntini M, Valvassori L, Serra M, Olivero M, Di Renzo MF, Colombo MP, et al. (2007). Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res 67, 7675-7685.
57. Cokakli M, Erdal E, Nart D, Yilmaz F, Sagol O, Kilic M, Karademir S, and Atabey N (2009). Differential expression of caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer 9, 65.
58. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, and Lisanti MP (2009). An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 8, 2420-2424.
59. Logozzi M, DeMilito A, Lugini L, Borghi M, Calabrò L, Spada M, Perdicchio M, Marino ML, Federici C, Iessi E, et al. (2009). High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 4, e5219.
60. Tanase CP, Dima S, Mihai M, Raducan E, Nicolescu MI, Albulescu L, Voiculescu B, Dumitrascu T, Cruceru LM, Leabu M, et al. (2009). Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. J Mol Histol 40, 23-29.
61. Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, Pestell RG, Sotgia F, Rui H, and Lisanti MP (2009). Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther 8, 1071-1079.
62. Cordes N, Frick S, Brunner TB, Pilarsky C, Grützmann R, Sipos B, Klöppel G, McKenna WG, and Bernhard EJ (2007). Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene 26, 6851-6862.
63. Regina A, Jodoin J, Khoueir P, Rolland Y, Berthelet F, Moumdjian R, Fenart L, Cecchelli R, Demeule M, and Béliveau R (2004). Down-regulation of caveolin-1 in glioma vasculature: modulation by radiotherapy. J Neurosci Res 75, 291-299.
64. Palozza P, Sestito R, Picci N, Lanza P, Monego G, and Ranelletti FO (2008). The sensitivity to β-carotene growth-inhibitory and proapoptotic effects is regulated by caveolin-1 expression in human colon and prostate cancer cells. Carcinogenesis 29, 2153-2161.
65. Head BP, Patel HH, Tsutsumi YM, Hu Y, Mejia T, Mora RC, Insel PA, Roth DM, Drummond JC, and Patel PM (2008). Caveolin-1 expression is essential for N-methyl-D-aspartate receptor-mediated Src and extracellular signal-regulated kinase 1/2 activation and protection of primary neurons from ischemic cell death. FASEB J 22, 828-840.
66. Wary KK, Mariotti A, Zurzolo C, and Giancotti FG (1998). A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchoragedependent cell growth. Cell 94, 625-634.
67. Razani B, Woodman SE, and Lisanti MP (2002). Caveolae: from cell biology to animal physiology. Pharmacol Rev 54, 431-467.
68. Swaney JS, Patel HH, Yokoyama U, Head BP, Roth DM, and Insel PA (2006). Focal adhesions in (myo)fibroblasts scaffold adenylyl cyclase with phosphorylated caveolin. J Biol Chem 281, 17173-17179.
69. Barcellos-Hoff MH, Newcomb EW, Zagzag D, and Narayana A (2009). Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol 19, 163-170.